ACTRN12611000865910已完成3 期
A Phase III Randomised, Double-blind, Placebo-controlled Pragmatic Trial to Assess the Efficacy of Tranexamic Acid in Reducing the Blood Loss in Patients with Per-rectal Bleeding
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Written informed consent
- •Per rectum bleeding
- •Able to swallow study medications
排除标准
- •Subjects less than 18 years
- •Patients with dementia or other health conditions that prevent a person from giving written informed consent.
- •History of thromboembolic disease or family history of same.
- •Subjects taking warfarin.
- •Subjects that are within 12 months of insertion of a drug-eluting stent.
- •Subjects that are within 12 weeks of placement of a bare metal stent.
- •Subjects that are pregnant and/or breastfeeding.
- •Subjects with a known gastrointestinal malignancy
- •Subjects with a known cancer in the palliative care phase of their treatment.
- •Subjects with a known allergy to tranexamic acid or its excipients.
研究者
相似试验
已完成
不适用
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent AsthmaPER-090-10Boehringer Ingelheim,22
已完成
3 期
Efficacy and Safety Study With BI 10773 vs. Placebo as add-on to Metformin or Metformin Plus Sulfonyurea Over 24 Weeks in Patients With Type 2 DiabetesCTRI/2010/091/001299Boehringer Ingelheim Pharma GmbH Co KG1,390
未知
3 期
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFalpha AgentsRheumatoid ArthritisJPRN-jRCT2080222045ovartis Pharma K.K.234
已完成
不适用
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) STORM-D015 Liver, gallbladder and bile ductsLiver, gallbladder and bile ductsD015PER-145-08BAYER S.A.,
进行中（未招募）
1 期
Phase III, double-blinded study using AZD7442 or Placebo for the prevention of COVID-19 disease in adults who have not been exposed to COVID-19 infectioCOVID-19MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-004356-16-FRAstraZeneca AB5,000